

A heteromeric TRP channel that functions as a WNT-activated G protein-coupled receptor

Received: 17 June 2025

Accepted: 11 February 2026

Cite this article as: Hardy, E.P., Haider, A.N., Patel, M.M. *et al.* A heteromeric TRP channel that functions as a WNT-activated G protein-coupled receptor. *Nat Commun* (2026). <https://doi.org/10.1038/s41467-026-69932-w>

Emily P. Hardy, A. Nasim Haider, Maulin M. Patel, Vasyl Nesin, Hanh T. M. Hoang, Sandra E. Gostynska, William L. Berry, Augen A. Pioszak, Mohiuddin Ahmad, Stephen C. Parnell & Leonidas Tsiokas

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

A heteromeric TRP channel that functions as a WNT-activated G protein-coupled receptor

Emily P. Hardy¹, A. Nasim Haider¹, Maulin M. Patel¹, Vasyl Nesin¹, Hanh T.M. Hoang¹, Sandra E. Gostynska², William L. Berry³, Augen A. Pioszak², Mohiuddin Ahmad¹, Stephen C. Parnell⁴, & Leonidas Tsiokas^{1*}

¹Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ²Department of Biochemistry and Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ³Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ⁴Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, USA.

*email: leonidas-tsiokas@ou.edu

Abstract

The human genome contains approximately 800 G protein-coupled receptors (GPCRs), all characterized by a common 7-transmembrane domain architecture. Here, we show that PKD1, an 11-transmembrane protein with a noncanonical transient receptor potential (TRP) channel architecture, functions as a GPCR with unique biochemical properties. PKD1 acts as a WNT-activated receptor, directly coupling to heterotrimeric $G_{\alpha_{i1-3}}$ subunits to inhibit cellular cAMP accumulation. While PKD1 contains both ligand-binding and G protein recruitment sites, PKD2, an associating TRP channel subunit, chaperones PKD1 to the plasma membrane to operate as a GPCR. This represents a striking departure from classical GPCR architecture and expands the functional repertoire of the TRP channel family. Given that mutations in either PKD1 or PKD2 are linked to autosomal dominant polycystic kidney disease, a multisystemic disorder marked by elevated cAMP levels, our results provide molecular insights into disease pathogenesis and highlight potential new therapeutic avenues for this debilitating and costly condition.

Introduction

Vertebrate genomes contain ~1,000 G protein-coupled receptors (GPCRs), forming the largest class of cell surface receptors mediating a plethora of cellular functions. All known GPCRs have a structural signature consisting of a 7-transmembrane (TM) domain flanked by an extracellular N-terminal segment and an intracellular C-terminal tail. Coupling of these receptors to a diverse group of heterotrimeric G proteins leads to the generation of second messengers, such as signaling lipids, Ca^{2+} , and cAMP, that initiate a complex array of cellular responses¹⁻³.

Autosomal dominant polycystic kidney disease (ADPKD), a multisystemic genetic disease affecting roughly 12.5 million people worldwide,^{4,5} has been mechanistically linked to altered cAMP metabolism⁶⁻⁹. ADPKD is caused by heterozygous germline mutations in *PKD1* and *PKD2* genes¹⁰⁻¹². PKD1 is a large (~500 kDa) integral membrane protein with 11 membrane-spanning segments¹³, an extensive extracellular N-terminal fragment, and an intracellular C-terminal tail¹⁴. PKD2 (~130 kDa) spans the membrane 6 times and belongs to the transient receptor potential (TRP) ion channel superfamily^{12, 15}. PKD1 and PKD2 assemble to form a heteromeric complex with a noncanonical “TRP” channel architecture¹⁶ for which the function has not been clearly defined. A unique and paradoxical feature of the PKD1/PKD2 complex is that the side chains of three positively-charged residues of PKD1 protrude into the ionic pore of PKD2 rendering it unlikely to conduct Ca^{2+} and other cations. Thus, while these subunits do assume a TRP-like pore architecture, their function as a cation-permeable channel complex is unsettled.

Evidence accumulated over 30 years has shown that cells derived from ADPKD patients have abnormally high cytosolic cAMP levels⁶⁻⁹ and an aberrant response to cAMP¹⁷, which is critical for disease development. Deletion of phosphodiesterase 1 and 3 family members (*Pde1a*, *Pde1c*, and *Pd3a*) aggravate PKD¹⁸, and pharmacologic inhibition of PDE4 promotes

cystogenesis in mouse *Pkd1*-null embryonic kidneys¹⁹. Conversely, pharmacologic and genetic manipulations to lower cAMP suppress cyst progression and improve renal function²⁰⁻²². These studies culminated in the identification of Tolvaptan, which serves as the only FDA-approved agent for the treatment of ADPKD²³⁻²⁵. Tolvaptan is a potent antagonist of the vasopressin 2 receptor²⁶, which is coupled to the heterotrimeric $G\alpha_s$ subunit leading to cAMP production. Whilst the use of Tolvaptan is limited to a subset of ADPKD patients due to side effects, these studies collectively suggest that elevated cellular cAMP concentration is a driver of cystogenesis in ADPKD. However, as the molecular function(s) of PKD1 and PKD2 remain elusive, a major knowledge gap is the mechanisms by which PKD1 and/or PKD2 keep cytosolic levels of cAMP in check.

Fragmented evidence suggests that PKD1 may function as an atypical GPCR²⁷. Indirect support for the function of PKD1 as a GPCR comes from the presence of a GPCR-autoproteolysis-inducing (GAIN) domain in its ectodomain, a defining feature of cell adhesion GPCRs^{28, 29}. However, there is no evidence linking autoproteolysis to cAMP regulation. Independent biochemical studies show that several $G\alpha$ subunits can directly bind the C-terminal tail of PKD1^{30, 31}, and a naturally occurring PKD1 mutation (L4132 Δ) within a predicted G protein-binding motif leads to severe cystic disease³². Finally, functional studies using various cell culture heterologous systems³³⁻³⁷, a mouse model³⁸, or the *Xenopus* pronephric model system support the role of PKD1 in GPCR-mediated signaling³¹. However, direct evidence that PKD1 functions as a GPCR in response to a specific ligand in any system is lacking. Combined with the fact that PKD1 lacks the typical '7-TM' signature architecture of classical GPCRs, these knowledge gaps have left the questions open of whether PKD1 is truly a GPCR and, if so, how this function is linked to cellular cAMP levels.

Results

Activation of PKD1 by WNT ligands induces $G\alpha$ - $G\beta\gamma$ dissociation

We have shown previously that WNT-9B functions as the activating ligand of PKD1 in a signaling pathway determining kidney tubular diameter during renal development³⁹. Disruption of this pathway results in the failure of developing tubules to achieve and maintain the proper tubular diameter leading to cystogenesis^{40, 41}. Here, we sought to determine whether PKD1 mediates heterotrimeric G protein activation in response to WNT-9B. Activated GPCRs promote the exchange of GDP for GTP on $G\alpha$ subunits followed by the dissociation of $G\alpha$ -GTP and free $G\beta\gamma$ ¹. To assess PKD1-mediated $G\alpha$ - $G\beta\gamma$ dissociation, we employed a set of bioluminescence resonance energy transfer (BRET)-based G protein activity sensors (G-CASE) covering all four major G protein families⁴². These sensors comprise $G\alpha$, $G\beta$, and $G\gamma$ on a single plasmid, with $G\alpha$ subunits tagged with the luminescent donor, NanoLuciferase (Nluc), and $G\gamma$ subunits N-terminally labeled with circularly permuted Venus (cpVenus¹⁷³) to serve as the acceptor fluorophore (Fig. 1a). We conducted Δ BRET time courses for six of the available G protein sensors in human embryonic kidney (HEK) 293T cells transiently co-transfected with the different biosensors and PKD1 (Fig. 1b-g). Kinetic analysis covered a time span of 10 minutes, 1 minute before and 9 minutes after stimulation with 1 μ g/ml (30 nM) WNT-9B or vehicle control. WNT-9B did not induce the dissociation of $G\alpha_s$ or $G\alpha_{13}$ (Fig. 1b and c). However, WNT-9B induced PKD1-mediated dissociation of $G\alpha_q$ and $G\alpha_{11-3}$, with the largest response seen for $G\alpha_{13}$ (Fig. 1d-h). The EC_{50} for WNT-9B was 405.6 ng/ml (11 nM) (Fig. 1i), which was consistent with the estimated EC_{50} of WNT-9B binding to extracellular fragments of PKD1³⁹ and channel activation⁴³. The magnitude of PKD1-mediated $G\alpha_{13}$ activation by WNT-9B was comparable to the magnitude of responses elicited by the activation of known GPCRs, such as the muscarinic acetylcholine receptor M1 (M1R) and calcium-sensing receptor (CaSR) using G-CASE sensors (Supplementary Fig. 1a and b). Cell surface expression of PKD1 was confirmed using a BRET-

based saturation assay, human PKD1 C-terminally-tagged with Nluc (PKD1-Nluc) was titrated with increasing concentrations of a HaloTag-fused cell surface marker bearing the RAS CAAX motif⁴⁴ (Supplementary Fig. 1c). Specificity of this interaction is indicated by saturable binding (Supplementary Fig. 1d). Live-cell imaging verified expression of PKD1-eGFP at the cell surface, as seen by co-localization with HaloTag-fused CAAX (Supplementary Fig. 1e).

Next, we determined if G protein selectivity differs in response to various WNT family members, as we have shown that in addition to WNT-9B, WNT-5A and WNT-3A bind the extracellular domain of PKD1³⁹. These experiments offered a unique opportunity to compare (a) canonical/ β -catenin dependent (WNT-3A), (b) noncanonical/ β -catenin independent (WNT-5A), and (c) mixed (both canonical and noncanonical, i.e., WNT-9B) pathway activating WNTs. Similarly to WNT-9B, neither WNT-5A nor WNT-3A stimulated coupling between PKD1 and G_{α_s} or $G_{\alpha_{13}}$ (Fig. 1b and c). PKD1- G_{α} selectivity in response to WNT specificity is demonstrated by the reduction in the rate of G_{α_q} , $G_{\alpha_{11}}$, and $G_{\alpha_{12}}$ dissociation from $G_{\beta\gamma}$ induced by WNT-3A compared to other WNTs. WNT-3A induced slower dissociation of these subunits compared to WNT-5A and WNT-9B (Fig. 1d-f and h). Maximal dissociation of $G_{\alpha_{13}}$ was seen with all three WNT ligands (Fig. 1g and h). The slower G_{α_q} dissociation by WNT-3A compared to the other two WNTs raises the possibility that ligand binding specificity, perhaps by involving different subdomains in the extracellular domain of PKD1 and/or co-receptors, determines selectivity in heterotrimeric G protein coupling. The overall BRET response and relative PKD1-mediated dissociation rates of all six G_{α} subunits in response to three WNT ligands are shown in the heat map diagrams (Fig. 1h).

FZD6 has been shown to couple to G_{α_q} and G_{α_i} subunits in response to WNT activation⁴⁵, thus, we sought to determine whether FZD6 and possibly other FZDs endogenously present in

HEK293T cells could account for PKD1-induced $G_{\alpha_{i3}}$ -CASE activation in response to WNT-9B. ZNRF3 is an E3 ubiquitin ligase that constitutively clears FZDs and LRP6 from the cell surface⁴⁶. Co-expression of ZNRF3 and PKD1 did not affect the magnitude or kinetics of WNT-9B-induced $G_{\alpha_{i3}}$ dissociation from $G\beta\gamma$, indicating that endogenous FZDs could not account for the activation of the $G_{\alpha_{i3}}$ -CASE sensor by PKD1 (Supplementary Fig. 1g). The functionality of ZNRF3 was confirmed by its effect on overexpressed FZD6-induced activation of $G_{\alpha_{i3}}$ -CASE (Supplementary Fig. 1h). To provide additional evidence for the preference of PKD1 towards $G_{\alpha_{i3}}$ we determined the effect of G protein signaling modulator 1 (GPSM1), which functions as a $G_{\alpha_{i3}}$ -specific guanine nucleotide dissociation inhibitor⁴⁷, on WNT-9B-induced dissociation of $G_{\alpha_{i3}}$ via PKD1. Co-expression of GPSM1 suppressed PKD1-mediated $G_{\alpha_{i3}}$ dissociation in response to WNT-9B (Supplementary Fig. 1i). Altogether, these data suggested that WNT ligands induce the dissociation of $G_{\alpha_{i1-3}}$ and G_{α_q} , but not G_{α_s} or $G_{\alpha_{13}}$ subunits from $G\beta\gamma$ via PKD1. These effects do not seem to involve endogenous FZD receptors and LRP6 co-receptors in transiently transfected HEK293T cells.

WNTs did not induce significant G_{α} dissociation for any of the six subtypes in mock (sensor only)-transfected cells in response to WNT ligands ($\leq 5\%$ drop in normalized BRET, Supplementary Fig. 1f) 48 hours following transfection or 24 hours post-seeding onto 96-well plates. However, 72 hours after transfection or 48 hours post-seeding, cells showed higher activity (up to 20% drop in normalized BRET) in response to WNT-9B in the absence of transfected PKD1 (Fig. 1j), perhaps by allowing more time to recover endogenous PKD1 from trypsinization after replating. We took advantage of this high signal-to-noise BRET ratio under these conditions to test whether endogenous PKD1 contributed to the WNT-induced activation of $G_{\alpha_{i3}}$. We knocked out human PKD1 using a combination of 3 human PKD1-specific sgRNAs and tested for WNT-9B-induced reduction of the $G_{\alpha_{i3}}$ -CASE sensor activity 72 hours following

transfections (Fig. 1j). Knockout efficiency was quantitatively determined (95%) on PKD1-Nluc 72 hours following transfection (Fig. 1k). Knockout of endogenous PKD1 led to a reduction in normalized BRET compared to sensor-only-transfected cells in response to WNT-9B. To confirm that this effect was PKD1-specific, we added back mouse PKD1, which is resistant to knockout by any of the 3 sgRNAs used to inactivate human PKD1. Mouse PKD1 rescued the effect of human PKD1 knockout (Fig. 1j, red versus purple). These data reveal an essential role of endogenous PKD1 in the WNT-9B-induced activation of $G\alpha_{i3}$.

To further confirm the specificity of our results and obtain mechanistic insights of how PKD1 functions as a WNT-activated GPCR, we tested the effects of several PKD1 mutations (Fig. 2a) on $G\alpha_{i1-3}$ dissociation from $G\beta\gamma$ in response to WNT-9B (Fig. 2b-d). S99I is a pathogenic mutant that compromises PKD1 cell surface expression³⁹, and thus, it should reduce receptor function. Indeed, expression of PKD1-S99I failed to induce $G\alpha$ - $G\beta\gamma$ dissociation. Similar results were obtained with W139C, also a pathogenic mutation located within the WNT-9B binding site. A similar effect was seen by the L4132 Δ mutation, which contains a pathogenic in-frame deletion of L4132 localized within a predicted G protein-binding domain in the C-terminal tail of PKD1³². Interestingly, the T3409V mutation, which renders PKD1 unable to undergo GAIN-mediated autoproteolysis²⁹, led to an approximately 50% reduction in heterotrimeric G protein signaling ($G\alpha_{i3}$ -CASE, Fig. 2d). This result is consistent with the hypomorphic function of this mutation in mice²⁹. Finally, the longest known pathogenic mutation, S4213X, truncates PKD1 by deleting the majority of its cytosolic C-terminal tail including the coiled-coil domain essential for interaction with PKD2, and resulted in complete loss of receptor function. Expression levels of mutants in transiently transfected HEK293T cells are shown in Supplementary Fig. 2. Altogether, these data agree with *in vivo* effects, supporting a biological role of PKD1 as a WNT-activated GPCR.

Next, we wanted to assess the mechanism of G protein coupling selectivity for PKD1 and compare this with the mechanism of canonical GPCRs. In the conventional mechanism of G protein activation, the distal portion of the $G\alpha$ C-terminal alpha helix engages the TM domains of the receptor during coupling (Fig. 3a and c)^{48, 49}. We designed chimeras for $G\alpha_s$ -CASE and $G\alpha_{i3}$ -CASE, in which the 16 final C-terminal amino acids were exchanged with that of the other (Fig. 3b and d) and conducted BRET assays as described previously to determine whether the $G\alpha$ C-terminus is a key component of coupling selectivity for PKD1 in response to WNT-9B (Fig. 3e). As expected, the exchange of the $G\alpha_{i3}$ C-terminus for that of $G\alpha_s$ ($G\alpha_{i3-s}$) led to a reduction in the maximum response compared to the wild-type $G\alpha_{i3}$. Interestingly, the $G\alpha_s$ to $G\alpha_{i3}$ C-terminal swap ($G\alpha_{s-i3}$) only resulted in a partial gain of function. A range of G protein sensor concentrations were tested to account for possible expression issues, yet the maximum response was still seen using the same concentration as the wildtype sensor (Supplementary Fig. 3a). We also confirmed these results were PKD1-specific, as sensor-only-transfected cells did not produce any response upon WNT stimulation (Supplementary Fig. 3b and c). In contrast to PKD1, $G\alpha_i$ -coupled CaSR and $G\alpha_s$ -coupled beta-2 adrenergic receptor (β_2 AR) each showed a complete exchange in coupling selectivity correlating with the swap in $G\alpha$ C-terminal motif (Fig. 3f and g), validating the functionality of the chimeras. Compared to the CaSR and β_2 AR, our results for PKD1 indicate that the $G\alpha$ C-terminus contributes only partially to selective coupling and suggests additional/multiple interactions between PKD1 and the G protein may dictate selectivity. Thus, the mechanisms dictating G protein coupling selectivity of PKD1 is likely different from traditional 7-TM containing GPCRs.

WNT-9B induces the recruitment of $G\alpha$ subunits to PKD1 and $G\alpha$ -GDP to $G\alpha$ -GTP exchange

A hallmark of heterotrimeric G protein activation downstream of a GPCR is the exchange of GDP for GTP on $G\alpha$ subunits following the recruitment of $G\alpha$ subunits to the receptor¹. Thus, we sought to determine whether PKD1 and $G\alpha_{i1-3}$ and $G\alpha_q$ subunits are recruited to PKD1 in response to WNT-9B activation. In this series of experiments, we used PKD1-Nluc and YFP-tagged $G\alpha_q$ and $G\alpha_{i1-3}$ subunits (Fig. 4a). Saturation experiments revealed saturable and thus specific interactions between PKD1 and $G\alpha_q$ or $G\alpha_{i1-3}$ subunits (Fig. 4b-e), and in response to WNT-9B, these subunits are recruited to PKD1 in a time-dependent manner (Fig. 4f-i). To determine whether WNT-9B induces a PKD1-dependent $G\alpha$ -GDP to $G\alpha$ -GTP exchange, we employed a collection of biosensors (ONE-GO sensors) to measure G protein activation⁵⁰ (Fig. 4a). WNT-9B induced GDP to GTP exchange on $G\alpha_q$ and $G\alpha_{i1-3}$ subunits (Fig. 4j-m), but not $G\alpha_s$ or $G\alpha_{13}$ (Supplementary Fig. 4a and b). Altogether, these results are in complete agreement with results obtained using G-CASE biosensors, further supporting the hypothesis that PKD1 is directly coupled to heterotrimeric G protein signaling for a selective subset of $G\alpha$ subunits.

PKD2 enables PKD1 to function as a GPCR

PKD2 is endogenously expressed at detectable levels in HEK293T host cells (Supplementary Fig. 5a), which could influence the functional expression of PKD1 as a GPCR. Thus, we inactivated the endogenous *PKD2* gene via CRISPR/Cas9-mediated genome editing in these cells using a doxycycline-inducible Cas9 vector (Supplementary Fig. 5a, lane 4). The efficiency of the PKD2-specific CRISPR construct was confirmed on transfected human PKD2 (Supplementary Fig. 5b, lane 4). Inactivation of human PKD2 led to the loss of PKD1 receptor function, indicating that endogenous PKD2 was essential for the receptor function of PKD1 in HEK293T cells (Fig. 5a and Supplementary Fig. 5c and 4, gray versus red). The functional dependence of PKD1 on endogenous PKD2 was also tested in a previously characterized clone

of mouse inner medullary collecting duct (mIMCD-3) cells (Fig. 5b, gray versus red), in which endogenous *Pkd2* has been permanently inactivated⁵¹. Therefore, the requirement of endogenous PKD2 for the functional expression of PKD1 as a GPCR is demonstrated in two different cell lines.

To gain insight into the mechanism by which PKD2 supported the receptor function of PKD1, we used the following PKD2 variants: D511V (or D509V in mouse PKD2), E442G (mouse PKD2), W201A (or W199A in mouse PKD2), and F604P (or F602P in the mouse). The D509V mutation compromises PKD2 channel activity and impairs maturation and targeting of PKD1 to the plasma membrane⁵². W199A reduces channel activity of PKD2⁵³, whereas F602P increases PKD2 channel activity^{54, 55}. Finally, E442G does not affect channel function but impairs PKD2 trafficking to the primary cilium⁵⁶. Homozygous *Pkd2*^{lrm4} (E442G) mice show a strong PKD phenotype, indistinguishable from that produced by complete *Pkd1* or *Pkd2* deletion⁵⁷. Adding back PKD2-E442G or PKD2-D509V in PKD2-null cells failed to restore PKD1 activity (Fig. 5a, blue and green, respectively). Co-expression of PKD1-eGFP with wild-type untagged PKD2 or PKD2 C-terminally fused to HaloTag led to robust expression of both proteins at the plasma membrane (Fig. 5c and d). As expected, PKD2-D509V did not drive expression of PKD1-eGFP to the plasma membrane (Fig. 5c, D509V panels). Interestingly, PKD2-E442G also failed to target PKD1-eGFP to the plasma membrane (Fig. 5c, E442G panels). PKD1-Nluc co-localization with HaloTag-CAAX determined by BRET quantifiably support live-cell imaging data (Fig. 5e). Notably, overexpression of wild-type PKD2 increased overall levels of PKD1 (Fig. 5e and Supplementary Fig. 2), possibly via protein-protein-mediated stabilization, as has been shown using C-terminal tails of PKD1 and PKD2⁵⁸. PKD2-E442G showed reduced stabilization of PKD1 compared to wild type (Fig. 5e), implying that E442G may affect PKD1/PKD2 assembly. The E442G mutation is located in the TOP domain of PKD2, which forms a tetrameric structure with 4-fold symmetry in homomeric PKD2 complexes⁵⁹ and a similar

structure but with a 15° deviation from 4-fold symmetry in the heteromeric PKD1/PKD2 complex¹⁶. Since E442G did not impede channel function⁵⁶, we reasoned that it should not affect self-assembly but rather assembly with PKD1. As expected, BRET experiments showed highly-efficient energy transfer between wild-type PKD1-Nluc and PKD2-HaloTag (Fig. 5f). However, BRET was severely reduced by the E442G mutation (PKD2-E442G-HaloTag), suggesting that E442G interferes with PKD1/PKD2 complex assembly and thus fails to target PKD1 to the plasma membrane. Expression of human PKD2-W201A or human PKD2-F604P in HEK293T cells did not affect PKD1 expression at the plasma membrane (Fig. 5c, W201A and F604P panels). In agreement with this finding, expression of mouse PKD2-W199A or mouse PKD2-F602P in *Pkd2*-null HEK293T cells and human PKD2-W201A or human PKD2-F604P in *Pkd2*-null mIMCD-3 cells did not impair $G\alpha_{i3}$ dissociation from $G\beta\gamma$ in response to WNT-9B (Fig. 5a and b). Furthermore, treatment of wild-type mIMCD-3 cells with La^{3+} which blocks cation permeation of PKD1/PKD2³⁹, PKD2, or even structurally related PKD2-L1⁶⁰ did not have a significant effect on the GPCR function of PKD1 (Fig. 5b). Collectively, these data suggest that PKD2 enables PKD1 to function as a GPCR by chaperoning it to the plasma membrane, independently of its channel function (Fig. 5g). They further implicate the loss of PKD1 GPCR function as an alternative mechanism underlying the cystogenesis observed in *Pkd2^{lrm4}* (E442G) mice⁵⁷.

PKD1-mediated $G\alpha_{i1-3}$ activation inhibits cAMP accumulation

$G\alpha_{i1-3}$ signaling leads to inhibition of cAMP accumulation (Fig. 6a). Therefore, we tested whether overexpression of PKD1 can inhibit basal or forskolin-induced cAMP accumulation in response to WNTs. We employed GloSensor technology, a cAMP assay to monitor changes in cytosolic cAMP levels in PKD1-transfected cells using two complementary strategies: (i) cells were treated with a concentration of forskolin close to its EC_{50} ($10^{-6}M$) (Fig. 6b and c) and soluble

WNTs were added when cAMP had reached its half-maximal concentration (Fig. 6c). In strategy (ii), endpoint analysis was used whereby PKD1-transfected cells were pretreated overnight with pertussis toxin (PTX, 100 ng/ml) to block $G_{\alpha_{i1-3}}$ signaling, then treated with forskolin in the presence or absence of soluble WNTs for 10 minutes and cAMP levels determined (Fig. 6d). Kinetic analysis showed that WNTs suppressed the dynamic accumulation of cAMP via PKD1 (Fig. 6c). WNT-3A had the lowest effect (Fig. 6c), which was consistent with the fact that it is most efficiently coupled to $G_{\alpha_{i3}}$ (Fig. 1g and h), which shows lower endogenous expression than $G_{\alpha_{i2}}$ in HEK293T cells (Supplementary Fig. 6a). $G_{\alpha_{i1}}$ is practically undetectable in HEK293T cells (Supplementary Fig. 6a). Similar results were obtained using the endpoint analysis, whereby PTX suppressed WNT-induced inhibition of cAMP accumulation (Fig. 6d). We next asked whether WNT ligands can lower basal (resting) levels of cytosolic cAMP in the presence of PKD1. WNT-9B induced a time-dependent reduction in cytosolic cAMP concentration in cells transfected with PKD1 (Fig. 6e, left trace). A similar but smaller effect was seen with WNT-5A or WNT-3A (Fig. 6e, center and right traces, respectively). The PKD1-mediated reduction in basal cAMP levels in response to WNT-9B was approximately half of the response elicited by the well-characterized muscarinic acetylcholine receptor M2 (M2R) following activation with carbachol in HEK293T cells (Supplementary Fig. 6b). Expression of pathogenic PKD1 mutants showed markedly suppressed inhibition of steady-state cAMP levels compared to wild-type PKD1 (Fig. 6f). To determine whether PKD2 had an essential role in WNT-induced inhibition of cAMP concentration via PKD1, we used our endpoint analysis for cAMP in cells lacking endogenous PKD2 and cells in which wild-type PKD2 was added back. These experiments support the role of PKD2 in inhibiting forskolin-induced cAMP accumulation in response to WNT-9B (Fig. 6g). We confirmed these results in wild-type and *Pkd2*-null mIMCD-3 cells using the end-point analysis. WNT-9B produced a significant reduction in forskolin-induced cAMP levels in wild-type, but not in *Pkd2*-null cells (Fig. 6h). Interestingly, deletion of *Pkd2* did not affect resting

cAMP levels. In summary, these data suggest that $G_{\alpha_{i1-3}}$ signaling mediated by WNT-induced activation of PKD1 is sufficient to reduce steady-state and forskolin-induced cAMP accumulation and this regulation is compromised in *Pkd2*-null cells (Fig. 6i).

GRK6 promotes the internalization of PKD1 and suppresses PKD1-mediated signaling

Typically, GPCR signaling is regulated through the process of desensitization, whereby G protein-coupled receptor kinases (GRKs) are recruited to the activated receptor to phosphorylate specific sites, “priming” the receptor for recruitment of beta-arrestins (ARRBs), which signal receptor internalization and degradation or recycling. Alternatively, GRK recruitment can initiate ARRB-dependent signaling that is independent of $G_{\alpha}/G_{\beta\gamma}$ signaling. In either case, some intrinsic affinity of the receptor for GRKs is needed to initiate desensitization and/or ARRB-based signaling. Based on this, we tested whether PKD1 is localized proximally to GRK2, GRK3, GRK5, or GRK6. BRET experiments using PKD1-Nluc and the different GRK subtypes fused to HaloTag revealed saturable and specific recruitment of GRK2, GRK5, and GRK6, but not GRK3 to PKD1-Nluc (Fig. 7a-d). Interestingly, the maximum BRET between PKD1 and GRK6 was increased upon overexpression of PKD2, but to a lesser degree by overexpression of PKD2- Δ C which lacks the C-terminal tail of PKD2 (Fig. 7d) and fails to target PKD1-eGFP to the plasma membrane (Fig. 7f). The opposite effect was seen with GRK2 (Fig. 7c). Since GRK2 is expressed predominantly in the cytoplasm, while GRK6 is anchored to the plasma membrane via palmitoylation modifications in its C-terminus⁶¹, these data suggest that PKD2 targets the PKD1/PKD2 complex to the plasma membrane where the complex is then in proximity to GRK6. This interpretation is consistent with the reduction in BRET between PKD1-Nluc and GRK2-HaloTag in the presence of PKD2 (Fig. 7c). The PKD2- Δ C construct fails to facilitate co-localization of PKD1 with GRK6 (Fig. 7e, lower panels) because it does not target the complex to the cell surface. To determine whether GRK6 functionally affects PKD1 coupling

to $G\alpha_{i3}$, we tested whether it promotes internalization and negatively affects WNT-induced PKD1 signaling. Overexpression of GRK6 did not affect overall receptor levels (Fig. 7g, right bar graph) but did result in the reduction of PKD1 from the cell surface (Fig. 7g, left bar graph) and WNT-induced PKD1-mediated $G\alpha_{i3}$ dissociation from $G\beta\gamma$ (Fig. 7h, DMSO). Inhibition of GRK6 activity using two different GRK6 inhibitors, GRK6-IN-1 or GRK6-IN-2, for 1 hour prior to WNT-9B activation partially reverted PKD1/PKD2-mediated $G\alpha_{i3}$ coupling in the presence of GRK6, indicating that the kinase activity of GRK6 was essential for its effect on PKD1/PKD2 function (Fig. 7h). Given the short-term effect of GRK6 inhibition (1 hour due to the toxicity of the inhibitors) on PKD1 internalization, we consider the partial reversal on PKD1/PKD2 function significant.

ARRB2 functions downstream of GRK6 in mediating internalization of the PKD1/PKD2 complex

PKD1 has been shown to interact with ARRB2 via its Polycystin-1, lipoxygenase, and α -toxin (PLAT) domain located in the intracellular loop between the first and second TM domains⁶². BRET saturation assays confirmed specific binding of HaloTag-fused ARRB2, but not ARRB1, to C-terminally-tagged PKD1-Nluc (Fig. 8a and b). Kinetic analysis revealed time-dependent recruitment of ARRB2-HaloTag to PKD1-Nluc in response to WNT-9B, which was unaffected by overexpression of PKD2 (Fig. 8c). However, time-dependent recruitment of ARRB2-HaloTag to Nluc-tagged PKD2 (PKD2-Nluc) was found to be PKD1-dependent (Fig. 8c), suggesting that recruitment of ARRB2 to PKD2 is indirect via PKD1 and that ARRB2 is recruited to the PKD1/PKD2 complex. WNT-9B-induced recruitment of ARRB2-HaloTag to PKD1-Nluc was reduced when cells were first incubated with GRK6 inhibitors, supporting the role of endogenous GRK6 in the recruitment of ARRB2 to the PKD1/PKD2 complex (Fig. 8d).

To provide further evidence that the PKD1/PKD2 complex rather than PKD1 alone is necessary for GPCR function at the plasma membrane, we determined the kinetics for WNT-9B-induced internalization of PKD1-Nluc and PKD2-Nluc from the plasma membrane and for accumulation of these proteins in early endosomes. We reasoned that if PKD2 has an initial chaperone function to deliver PKD1 to the cell surface and then to dissociate from PKD1 after successful delivery, PKD2 would not show the same time-dependent internalization as PKD1 in response to a ligand. Fig. 8e-g shows that this is not the case. Steady-state BRET measurements and super-resolution imaging confirmed proximity and co-localization of PKD1-Nluc or PKD2-Nluc to HaloTag-Rab5 and HaloTag-FYVE1 (Fig. 8e and Supplementary Fig. 7) which marks the early endosome. WNT-9B stimulation in BRET time-course assays revealed similar kinetic profiles for PKD1-Nluc and PKD2-Nluc for both internalization and accumulation in the early endosome (Fig. 8f). The internalization of PKD1 in response to WNT-9B was inhibited by barbadin, an ARRB inhibitor (Fig. 8g). These results indicate that PKD2 remains associated with PKD1 during ligand activation and both proteins move together to the early endosome following activation (Fig. 8h).

Discussion

Collectively, our data show that PKD1 mediates outside-in signaling, leading to the reduction of cAMP levels via direct coupling to $G_{\alpha_{1-3}}$ subunits in response to WNT ligands. PKD1-mediated activation of G protein signaling is independent of FZD receptors and occurs immediately after the addition of soluble WNTs, representing the fastest response of PKD1 to an activating event that we observed. PKD1 is the first example of an integral membrane protein without the 7-TM protein domain of typical GPCRs that can be efficiently coupled to heterotrimeric G proteins. Direct coupling of PKD1 to G protein signaling is supported by three lines of complementary evidence: (a) WNT-induced PKD1-mediated G_{α} - $G\beta\gamma$ dissociation detected by G-CASE sensors, (b) G_{α} -GDP to G_{α} -GTP conversion detected by ONE-GO sensors, and (c) direct WNT-induced

G α subunit recruitment to PKD1. While it has been speculated that PKD1 may function as a GPCR²⁸, this hypothesis has never been tested directly in real time using full-length PKD1 activated in a ligand-dependent manner. Our studies clearly show that this new role for PKD1 is the case. Based on our previous studies, whereby soluble ligands bind with high affinity to a short segment of the extracellular domain of PKD1³⁹, we propose that WNT ligands stabilize PKD1 in an active conformation that allows it to interact with G α_{i1-3} and G α_q subunits, leading to their activation.

Our data support the hypothesis that PKD2 assembles with PKD1 and facilitates its targeting to the plasma membrane where they can function together as a complex. The channel activity of PKD2 is not required for the function of the complex as a GPCR. These conclusions are supported by the following lines of evidence: a) the D509/511V PKD2 variant fails to target PKD1 to the plasma membrane and does not support its function as a GPCR, b) E442G, which compromises complex assembly has similar effects on targeting PKD1 to the cell surface and GPCR function, c) W199A/201 or F602/604P, which function diametrically opposite in regard to PKD2 channel activity, do not affect PKD1/PKD2's GPCR function, d) pre-treatment the cells with La³⁺, a non-specific inhibitor of the cation permeation of PKD1/PKD2, PKD2, or a structurally-related PKD2-L1 channel did not affect GPCR function of PKD1, and e) PKD1 or PKD2 follow the same time-dependent removal from the cell surface and accumulation in the early endosome in response to a WNT ligand. As only activated receptors follow β -arrestin-mediated internalization, these data suggest that PKD1 and PKD2 remain bound together during ligand activation. Given that PKD2 does not directly interact with WNTs³⁹, the simpler conclusion is that the PKD1/PKD2 complex rather than PKD1 alone functions as a GPCR at the cell surface. Whether PKD2 has functions in addition to its chaperoning function to modulate GPCR signaling at the plasma membrane requires further work.

Previous work has shown that the C-terminal tail of PKD1 binds a wide spectrum of G proteins with the exception of $G_{\alpha_{13}}$ ^{30, 31, 63}. Knockdown of $G_{\alpha_{i1-3}}$ and all G_{α_q} homologs in *Xenopus* embryos leads to a PKD phenotype³¹. Furthermore, exogenous expression of full-length PKD1 or a 1,811 residue N-terminally truncated version activates $G_{\alpha_{i/o}}$ proteins in freshly isolated sympathetic neurons cells³⁷. Overexpression of PKD2 however, suppresses PKD1 coupling to $G_{\alpha_{i/o}}$ proteins³⁷. Similarly, constitutive activation of the PKD2 channel in dorsal root ganglia cells is suppressed by PKD1 overexpression³⁶. It was suggested that a critical balance of PKD1 and PKD2 is essential to maintain the complex in an inactive or “silent” state, so that it can be only activated by the appropriate stimulus³⁶. Our data support and extend this model in several respects: 1) both models converge to the point that PKD1 can activate G_{α_i} proteins, 2) our model extends the previous model by demonstrating that PKD1 directly activates G_{α_i} in response to an activating ligand, in real-time, 3) our model incorporates an essential role of endogenous PKD2 in the function of PKD1 as a GPCR, which was not examined in the 2002 study³⁷. 4) Both models support the concept that a critical balance of PKD1 and PKD2 is needed to achieve maximal GPCR activity. In the 2002 study, overexpression of PKD2 suppressed the PKD1-mediated activation of $G_{\alpha_{i/o}}$, and in our study excessive expression of PKD2 did not fully rescue PKD1/PKD2 function in *Pkd2*-null HEK393T or mIMCD-3 cells, probably by exceeding the threshold for the formation of functional complexes. The concept of a critical threshold for a functional PKD1/PKD2 complex formation is supported by *in vivo* experiments whereby transgenic mice overexpressing PKD1 or PKD2 show cystic disease^{64, 65}.

We show that PKD1 is directly and selectively coupled to $G_{\alpha_{i1-3}}$ and G_{α_q} subunits, but not to G_{α_s} or $G_{\alpha_{12/13}}$, in response to WNT ligands. The coupling of $G_{\alpha_{i1-3}}$ and ensuing inhibition of cAMP accumulation is extremely relevant to ADPKD, as abnormal cytosolic cAMP accumulation

and cAMP-dependent signaling are hallmarks of cystic cells derived from ADPKD patients or mice lacking *Pkd1* or *Pkd2*⁹. The prevailing dogma was that accumulated cAMP in these cells is due to reduced Ca²⁺ signaling mediated by the PKD1/PKD2 channel complex^{20, 66, 67}, thus a more downstream event. Our data support the alternative, but not mutually exclusive possibility that abnormally high levels of cytosolic cAMP levels are due to impaired G_{α₁₁₋₃} signaling at a much earlier stage directly involving PKD1/PKD2. As the receptor function of the PKD1/PKD2 complex does not require Ca²⁺ permeation, our data are compatible with cryo-EM data of the PKD1/PKD2 complex, whereby three positively charged amino acid residues of PKD1 occlude the PKD1/PKD2 ionic pore¹⁶. We hypothesize that while individual PKD1 and PKD2 proteins bear “TRP channel-like” domains, when they form a complex, not only is the channel function blocked, but a GPCR function is enabled. Whether channel activation is induced downstream of G protein dissociation requires further studies.

PKD1/PKD2 does not only mediate ligand-dependent G_α-mediated signaling, but also GRK/ARRB-mediated recruitment and internalization. We show that PKD1/PKD2 is in proximity to GRK6, whose activity contributes to PKD1/PKD2 internalization and ARRB2 recruitment. While we show ligand- and time-dependent recruitment of ARRB2 to PKD1 or PKD2, we could not demonstrate time-dependent recruitment of GRK6 to PKD1 or PKD2 in response to WNT-9B by BRET. We speculate that GRK6 and PKD1 are already in such proximity before receptor activation that “additional” GRK6 recruitment cannot be resolved using BRET. Although GRK6 belongs to a subset of GRKs including GRK4 and GRK5 that can constitutively phosphorylate GPCRs in the non-activated state^{68, 69}, we do not believe that GRK6 constitutively primes PKD1 for ARRB2 recruitment in the non-activated state, because ARRB2 does show ligand-dependent recruitment indicating that an activating event for ARRB2 recruitment is needed.

We show that PKD1 is a unique type of GPCR containing 11- rather than 7-TM segments typically seen in classical GPCRs. Notably, PKD1 has a distinct sequence and structure, not simply an additional extension of the “typical 7-TM protein” domain seen in canonical or non-traditional GPCRs, such as LYCHOS (or GPR155), a hybrid of a transporter and a GPCR containing a total of 17-TM helices⁷⁰. LYCHOS was shown to function as a GPCR^{71, 72}. Thus, our results expand the general signaling paradigm for the GPCR group of cell surface receptors. The unique structural features and functional properties of the Polycystin complex described here lead us to propose that the Polycystins (PKD1 and PKD2) and possibly Polycystin-like molecules (i.e., PKD1-L (1-3), PKD2-L (1-3)) form a new class of GPCRs. Consistently, PKD1-L2 binds a subset of $G\alpha$ subunits⁷³.

Our study has the following limitations. Most of the experiments were done using overexpression systems, where ratios of PKD1, PKD2, and various sensors were optimized for maximal coupling. However, these ratios may not represent physiological levels of endogenous components. This limitation was mitigated by loss-of-function experiments, where endogenous PKD1 or PKD2 was inactivated. In addition, the BRET assay does not detect direct protein-protein interactions, but proximity between two proteins down to 10 nm distance. Despite this caveat, it allows the detection of protein-to-protein recruitment in real time in response to a ligand, which is critical in our study. Finally, our study does not provide a structural basis for the PKD1/ $G\alpha$ protein coupling. To date, no high-resolution structure of full-length PKD1 has been feasible. The cryo-EM structure of a truncated PKD1/PKD2 complex has been reported¹⁶, but omits key regions of PKD1, including much of its extracellular, ligand binding and cytoplasmic domains that mediate G protein signaling. Without full structural coverage, critical aspects of PKD1's interaction with signaling proteins remain speculative. In summary, while the inability to structurally resolve full-length PKD1 remains a substantial limitation, this study successfully

circumvents these technical barriers shifting the field from correlative speculation to functional demonstration of the role of PKD1 as a ligand-responsive GPCR.

Overall, our data define the molecular function of the Polycystin complex and directly link it to cAMP metabolism, putting forth the notion that impaired PKD1-G α_{i1-3} coupling is the root cause of cyst formation in ADPKD. This idea gives a broader perspective of the mechanisms underlying cystogenesis in ADPKD and can serve as the springboard for future studies to address specific downstream functions of the PKD1 GPCR in ADPKD. Our results have implications in understanding biological processes that go far beyond ADPKD, as they shed light onto a wide spectrum of biological processes that involve WNT- and PKD1/PKD2-mediated signaling cascades. Therefore, understanding how this unique ligand/receptor system works will impact research efforts on many other biological processes in various tissues and organs.

Methods

Plasmids

Human wild-type PKD1-HA and human PKD1 T3049V were provided by Feng Qian. Human PKD1 L4132 Δ -HA and human PKD1 S4213X-HA were provided by Stephen Parnell³². Mouse PKD1-eGFP was provided by Chris Ward (University of Kansas Medical Center). Mouse Flag-PKD1 was provided by J. Yang (Columbia University). Human PKD1 gRNAs (1-3) and Cas9 were purchased from Addgene (cat #76841, #76842, #76843, and #52962, respectively). To generate human PKD1-Nluc, Nluc was cloned out of the pNLF1-C [CMV/Hygro] vector (Promega) and into PKD1-HA before the HA tag. Mouse PKD2 was made by PCR amplification of mouse cDNA derived from a mouse embryonic kidney cDNA library and cloned into pcDNA3. Human PKD1 W139C-HA³⁹, human PKD1 S99I-HA³⁹, mouse PKD2 E442G, mouse PKD2 D509V, mouse PKD2 W199A, mouse PKD2 F602P, human PKD2 W201A, and human PKD2 F604P were generated using the QuikChange mutagenesis kit (Agilent Technologies). Human PKD1 Δ C was generated by cytoplasmic C-terminal region deletion using pCS2+MT-6xMyc-hPKD2 (Addgene #21370). Mouse PKD2-HaloTag was generated by cloning the mouse PKD2 into the pHTC HaloTag CMV-neo vector (Promega), and mouse PKD2 E442G-HaloTag was generated by mutagenesis. Mouse PKD1-Nluc was generated by cloning the mouse PKD2 in the pNLF1-C [CMV/Hygro] vector (Promega). eTLCV-hPKD2 was generated by cloning the guide RNA for human PKD2 into a modified version (eTLCV2) of the TLCV2 vector backbone (Addgene #87360). Gs-CASE (Addgene #168124), G13-CASE (Addgene #168127), Gq-CASE (Addgene #168125), Gi1-CASE (Addgene #168120), Gi2-CASE (Addgene #168121), and Gi3-CASE (Addgene #168122) were gifts from Gunnar Schulte. The Gi3-s and Gs-i3 chimeras were made in the Gi3-CASE and Gs-CASE as follows: For the Gi3-s chimera, the final 16 C-terminal amino acids of human Gi3 were replaced with those of human Gs (CRDIIQRMHLRQYELL). For the Gs-i3 chimera, the final 16 amino acids of human Gs were replaced with those of human

Gi3 (VTDVIKNNLKECGLY). Galpha-s ONE-GO (Addgene #189731), Galpha-13 ONE-GO (Addgene #189740), Galpha-q ONE-GO (Addgene #189738), Galpha-i1 ONE-GO (Addgene #189735), Galpha-i2 ONE-GO (Addgene #189736), and Galpha-i3 ONE-GO (Addgene #189737) were gifts from Mikel Garcia-Marcos. Galpha-q-YFP, Galpha-i1-YFP, Galpha-i2-YFP, and Galpha-i3-YFP were generated by cloning out the IRES and Nluc components from the ONE-GO biosensors. Mouse GRK2-HaloTag, mouse GRK3-HaloTag, GRK5-HaloTag, human GRK6-HaloTag, ARRB1-HaloTag, ARRB2-HaloTag, HaloTag-CAAX, HaloTag-Rab5, and HaloTag-FYVE were obtained from Mohiuddin Ahmad. Human GRK6 and β 2AR were obtained from Augen Pioszak. M1R-HA and M2R were generated using RT-PCR from a human fetal kidney cDNA library. CaSR was obtained from Wenhan Chang (UCSF). Mouse FZD6 in SPORT6 was obtained from Horizon Discovery Collection of cDNA & ORF clones and verified by Sanger sequencing. ZNRF3 was obtained from Dr. Cong (Novartis). Human GPSM1 was purchased from Sino Biological (HG19737-UT). The pGloSensor-22F cAMP Plasmid was purchased from Promega.

Recombinant proteins and drugs

Recombinant human WNT-3A (5036-WN), human/mouse WNT-5A (645-WN), and mouse WNT-9B (3669-WN) were purchased from R&D Systems/Biotechne. WNTs were dissolved to 100 μ g/ml in filter-sterilized in PBS containing 0.1% bovine serum albumin (BSA) and stored at -20°C in low-protein binding microcentrifuge tubes (Eppendorf). For stimulation experiments, WNTs were diluted in Opti-MEM I Reduced Serum Medium, no phenol red (Gibco) containing 0.1% BSA. The following drugs were stored at -20°C as stock solutions and diluted in PBS or assay medium on the day of experiments: R568, Spermine, Carbachol, Isoproterenol, Doxycycline, Forskolin (Thermofisher, J63292.MA), Pertussis Toxin (Thermofisher, PHZ1174), GRK6-IN-1 (MedChemExpress, HY-142812), GRK6-IN-2 (MedChemExpress, HY-142817), and

Barbadin (MedChemExpress, HY-119706). Lanthanum was prepared from powder the day of the experiment (Sigma-Aldrich, 262072).

Cell lines

HEK293T cells (ATCC, CRL-3216) were maintained in DMEM (Corning) supplemented with 10% FBS (GeminiBio). Wild type and *Pkd2*-null mouse inner medullary collecting duct (mIMCD-3) cells were obtained from Dr. Steve Kleene⁵¹ and maintained in DMEM:F12 (Gibco) supplemented with 10% FBS. All cell lines were cultured in a humidified incubator at 37°C and 5% CO₂. Absence of mycoplasma contamination was routinely confirmed by PCR.

Transient transfections

On the day of transfection, cells were trypsinized and diluted in cell culture medium to a final density of 2×10^5 cells/ml. Subsequently, 2 ml of cell suspension (400,000 cells) was plated in each well in a sterile six-well plate and incubated for 4-6 hours at 37°C, 5% CO₂. HEK293T cells were transiently transfected using the calcium phosphate precipitation method. mIMCD-3 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. For all experiments, cells were transiently transfected with up to 4 µg total DNA per well in a 6-well plate. Transfected cells were then incubated for 24 hours at 37°C, 5% CO₂. Plasmid amounts and combination used for transient transfections are detailed in Supplementary Table 2.

Bioluminescence resonance energy transfer assays

24 hours post-transfection, cells were trypsinized and resuspended in cell culture medium. Following centrifugation, cells were resuspended in assay medium (Opti-MEM I Reduced Serum Medium, no phenol red, supplemented with 4% FBS) at a final density of 2×10^5 cells/ml, and 100 µl dispensed per well of a sterile white 96-well microplate (Greiner Bio-One) and incubated

for 24 hours at 37°C, 5 % CO₂. For BRET assays using Nluc- and HaloTag-fused proteins, half of the cells were treated with 100 nM HaloTag NanoBRET 618 Ligand (Promega) and the other half with 0.1% DMSO (no-ligand control), and 100 µl of both cell suspensions dispensed into separate wells. 24 hours post seeding, 25 µl of furimazine (Promega) was added to each well (final dilution 1:1,000) and incubated for 5 minutes at room temperature. All measurements were performed using a Synergy Neo2 hybrid multi-mode microplate reader (BioTek) equipped with filters to simultaneously measure the donor and acceptor emissions (450/50 and 610LP for BRET experiments with Nluc- and HaloTag-fused proteins, or 460/540 for experiments with G-CASE sensors, ONE-GO sensors, or G α -YFP), and using an integration time of 200 ms. For stimulation experiments, baseline measurements were acquired for five minutes before manual addition of 25 µl of compound or vehicle control (assay medium) to the final concentration indicated in individual figure panels and/or legends. Signal was then measured for an additional 10-20 minutes. Assays done using BRET-based G protein biosensors were conducted at 27°C. Assays to measure Nluc- and HaloTag-fused protein interactions were conducted at room temperature. BRET data were collected using BioTek Gen5 software for detection (Agilent).

Glosensor cAMP assays

Approximately 400,000 HEK293T cells were seeded on each well of 6-well plates and transfected with plasmids 18 hours later. Cell medium was replaced 6 hours after transfections and cells incubated 24 hours at 37°C with 5% CO₂. For experiments in which the PKD2 CRISPR KO was transfected, medium was supplemented with doxycycline (2 µg/ml). Subsequently, cells were rinsed with PBS, trypsinized, and resuspended in 2 ml of cell culture medium. Following centrifugation, cells were resuspended in fresh cell culture medium at a final density of 2×10^5 cells/ml, and 100 µl dispensed per well of a white 96-well microplate and incubated for 20 hours at 37°C, 5 % CO₂. For end-point analyses to determine PTX-sensitivity,

replacement medium was supplemented with 0.1 $\mu\text{g/ml}$ PTX. The following day, medium was replaced with 100 μl of equilibration medium (88% CO_2 -independent medium, 10% FBS, 2% GloSensor cAMP Reagent stock solution in HEPES buffer) per well. Cells were then incubated for 2 hours at room temperature. For dose-response experiments to assess forskolin-induced cAMP accumulation detection using the pGloSensor-22F cAMP biosensor, a pre-read measurement was taken followed by the addition of varying concentrations of forskolin. Luminescence was measured after 10 minutes, and this value was divided by the pre-read measurement to determine fold response. For end-point analysis, a pre-read measurement was taken before compound addition. WNT ligands (1 $\mu\text{g/ml}$) or vehicle were then manually added to wells using a multichannel pipet and incubated for 5 minutes. Subsequently, forskolin (1 μM) was then manually added to all wells, and luminescence was measured 25 minutes later. For kinetic analysis, the plate was pre-equilibrated to the steady-state operating temperature of the microplate reader before compound addition by performing a pre-read kinetic measurement for 10 minutes to monitor the basal level of luminescence. For experiments to determine the inhibitory effect of WNTs on FSK-induced cAMP, following the pre-read kinetic measurement, 1 μM forskolin was added manually to each well using a multichannel pipet. Measurements were continued for 10 minutes, followed by manual addition of WNT (1 $\mu\text{g/ml}$) or vehicle control, and the plate was read for an additional 10 minutes. For experiments to measure the agonist effect on basal cAMP levels, WNT ligands (1 $\mu\text{g/ml}$) or vehicle were manually added following the pre-read kinetic measurement and recordings continued for 10 minutes.

Live-cell imaging

HEK293T cells were transfected in 8-well chambered cover glasses (Cellvis) with expression plasmids. After a 24-hour incubation period post-transfection, cells were labeled with 200 nM JFX 554 HaloTag Ligand (Promega) for 30 min and cultured in phenol red-free Opti-MEM. Live-

cell imaging was done using an oil immersion 1.48 NA 100X objective lens in a Nikon CSU-W1 SoRa Spinning Disk confocal microscope. During image acquisition SoRa 2.8x magnification was used with laser power set at 85% 200 ms for 488 channel, and 10% 100 ms for the 561 channel, all with a step size of 0.1 μm . NIS Elements Software was used to process the images with the LUT set at 100-200 for the 488 channel.

Immunoprecipitations

In experiments where immunoprecipitations were done in lysates, cells were lysed in 1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl at pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, and 10% sucrose with protease inhibitor cocktail (Roche Applied Science) at 4°C for 30 min and lysates were collected by centrifugation (18,000 \times g, 20 min). Lysates (500 μl) were incubated at 4°C for overnight with indicated antibodies in figures coupled to Sepharose beads. Beads were pelleted by centrifugation, and pellets were washed in lysis buffer three times for 20 min with rotation at 4°C. Immunoprecipitated proteins immunoblotted with indicated antibodies in figures.

qRT-PCR

RNA was isolated from HEK293T cells using TRIzol reagent (Thermofisher) and further purified using Qiagen RNA isolation kit (Qiagen). cDNA was prepared from 500 ng RNA using Maxima First Strand cDNA Synthesis Kit (Thermofisher). qRT-PCR assays were performed using EvaGreen 2X qPCR MasterMix (Bullseye) and primers corresponding to the appropriate cDNA (Supplementary Table 1). Analysis was performed using Bio-Rad CFX96.

Statistics & Reproducibility

BRET ratios were defined as the acceptor emission divided by the donor emission. Normalized BRET was determined by subtracting the mean value of the baseline prior to stimulation from all

data points. Net BRET was calculated by subtracting the donor only (transfection without HaloTag or YFP) BRET ratio. To determine ligand-induced effects, Δ BRET was calculated as the difference between vehicle and WNT-treated wells, where each well was normalized to the mean value of the baseline. For analysis of G-CASE experiments, Δ BRET (%) was calculated for each well as a percent over the baseline $[(\text{BRET ratio (treated)} - \text{mean BRET ratio (baseline)}) / \text{mean BRET ratio (baseline)}] \times 100$. Subsequently, the average Δ BRET (%) of vehicle control was subtracted. Max Δ BRET (%) was defined as maximum change from the baseline following stimulation in the kinetic experiments. Area under curve (AUC) was determined for 6 minutes post-treatment. Saturation curves were fit using a one site-specific binding model. BRET_{max} denotes the maximum net BRET signal. BRET_{50} represents the acceptor/donor ratio required to reach the half-maximal BRET signal. Dose-response curves were fit using a nonlinear three-parameter model. For all statistical tests, $p < 0.05$ denoted by one asterisk was considered significant, and normality was confirmed. All data were analyzed with GraphPad Prism, and details of statistical analyses are provided in the source data file.

Data Availability

Source data are provided with this paper.

References

1. Weis, W.I. & Kobilka, B.K. The Molecular Basis of G Protein-Coupled Receptor Activation. *Annu Rev Biochem* **87**, 897-919 (2018).
2. Liu, S., Anderson, P.J., Rajagopal, S., Lefkowitz, R.J. & Rockman, H.A. G Protein-Coupled Receptors: A Century of Research and Discovery. *Circ Res* **135**, 174-197 (2024).
3. Nürnberg, B., Beer-Hammer, S., Reisinger, E. & Leiss, V. Non-canonical G protein signaling. *Pharmacol Ther* **255**, 108589 (2024).
4. Harris, P.C. & Torres, V.E. Polycystic Kidney Disease, Autosomal Dominant, in *GeneReviews*(®). (eds. M.P. Adam *et al.*) (University of Washington, Seattle Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., Seattle (WA); 1993).
5. Grantham, J.J. Clinical practice. Autosomal dominant polycystic kidney disease. *N Engl J Med* **359**, 1477-1485 (2008).
6. Hjelle, J.T. *et al.* Autosomal recessive polycystic kidney disease: characterization of human peritoneal and cystic kidney cells in vitro. *Am J Kidney Dis* **15**, 123-136 (1990).
7. Belibi, F.A. *et al.* Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. *Kidney Int* **66**, 964-973 (2004).
8. Yamaguchi, T., Nagao, S., Kasahara, M., Takahashi, H. & Grantham, J.J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. *Am J Kidney Dis* **30**, 703-709 (1997).
9. Zhou, X. & Torres, V.E. Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling. *Front Mol Biosci* **9**, 981963 (2022).
10. Consortium, E.P.K.D. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney

- Disease Consortium [published errata appear in *Cell* 1994 Aug 26;78(4):following 724 and 1995 Jun 30;81(7):following 1170]. *Cell* **77**, 881-894 (1994).
11. Consortium, I.P.K.D. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. *Cell* **81**, 289-298 (1995).
 12. Mochizuki, T. *et al.* PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science* **272**, 1339-1342 (1996).
 13. Nims, N., Vassmer, D. & Maser, R.L. Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. *Biochemistry* **42**, 13035-13048 (2003).
 14. Hughes, J. *et al.* The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. *Nat Genet* **10**, 151-160 (1995).
 15. Tsiokas, L. *et al.* Specific association of the gene product of PKD2 with the TRPC1 channel. *Proc Natl Acad Sci U S A* **96**, 3934-3939 (1999).
 16. Su, Q. *et al.* Structure of the human PKD1-PKD2 complex. *Science* **361** (2018).
 17. Yamaguchi, T. *et al.* Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. *Kidney Int* **63**, 1983-1994 (2003).
 18. Ye, H. *et al.* Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. *J Am Soc Nephrol* **27**, 1312-1320 (2016).
 19. Pinto, C.S. *et al.* Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol* **27**, 1124-1134 (2016).
 20. Wang, Q. *et al.* Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease. *Kidney Int* **93**, 403-415 (2018).

21. Choi, Y.H. *et al.* Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. *Proc Natl Acad Sci U S A* **108**, 10679-10684 (2011).
22. Rees, S. *et al.* Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. *J Am Soc Nephrol* **25**, 232-237 (2014).
23. Zhou, J.X. & Torres, V.E. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon. *Adv Kidney Dis Health* **30**, 245-260 (2023).
24. Torres, V.E. *et al.* Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* **367**, 2407-2418 (2012).
25. Gattone, V.H., 2nd, Wang, X., Harris, P.C. & Torres, V.E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. *Nat Med* **9**, 1323-1326 (2003).
26. Yamamura, Y. *et al.* OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. *J Pharmacol Exp Ther* **287**, 860-867 (1998).
27. Sussman, C.R., Wang, X., Chebib, F.T. & Torres, V.E. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. *Cell Signal* **72**, 109649 (2020).
28. Maser, R.L., Calvet, J.P. & Parnell, S.C. The GPCR properties of polycystin-1- A new paradigm. *Front Mol Biosci* **9**, 1035507 (2022).
29. Yu, S. *et al.* Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. *Proc Natl Acad Sci U S A* **104**, 18688-18693 (2007).
30. Parnell, S.C. *et al.* The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro [In Process Citation]. *Biochem Biophys Res Commun* **251**, 625-631 (1998).

31. Zhang, B., Tran, U. & Wessely, O. Polycystin 1 loss of function is directly linked to an imbalance in G-protein signaling in the kidney. *Development* **145** (2018).
32. Parnell, S.C. *et al.* A mutation affecting polycystin-1 mediated heterotrimeric G-protein signaling causes PKD. *Hum Mol Genet* **27**, 3313-3324 (2018).
33. Parnell, S.C. *et al.* Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. *J Biol Chem* **277**, 19566-19572 (2002).
34. Parnell, S.C., Magenheimer, B.S., Maser, R.L. & Calvet, J.P. Identification of the major site of in vitro PKA phosphorylation in the polycystin-1 C-terminal cytosolic domain. *Biochem Biophys Res Commun* **259**, 539-543 (1999).
35. Kwak, M. *et al.* G α (i)-mediated TRPC4 activation by polycystin-1 contributes to endothelial function via STAT1 activation. *Scientific reports* **8**, 3480 (2018).
36. Delmas, P. *et al.* Gating of the polycystin ion channel signaling complex in neurons and kidney cells. *FASEB J* **18**, 740-742. Epub 2004 Feb 2006. (2004).
37. Delmas, P. *et al.* Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. *J Biol Chem* **277**, 11276-11283. Epub 12002 Jan 11210. (2002).
38. Kwon, M. *et al.* G-protein signaling modulator 1 deficiency accelerates cystic disease in an orthologous mouse model of autosomal dominant polycystic kidney disease. *Proc Natl Acad Sci U S A* **109**, 21462-21467 (2012).
39. Kim, S. *et al.* The polycystin complex mediates Wnt/Ca(2+) signalling. *Nat Cell Biol* **18**, 752-764 (2016).
40. Karner, C.M. *et al.* Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. *Nat Genet* **41**, 793-799 (2009).
41. Castelli, M. *et al.* Polycystin-1 binds Par3/aPKC and controls convergent extension during renal tubular morphogenesis. *Nature communications* **4**, 2658 (2013).

42. Schihada, H., Shekhani, R. & Schulte, G. Quantitative assessment of constitutive G protein-coupled receptor activity with BRET-based G protein biosensors. *Sci Signal* **14**, eabf1653 (2021).
43. Feng, S. *et al.* The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex. *J Am Soc Nephrol* **28**, 2973-2984 (2017).
44. George, K. *et al.* Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons. *iScience* **27**, 110047 (2024).
45. Kilander, M.B. *et al.* Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6. *Faseb j* **28**, 2293-2305 (2014).
46. Hao, H.X. *et al.* ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. *Nature* **485**, 195-200 (2012).
47. Bernard, M.L., Peterson, Y.K., Chung, P., Jourdan, J. & Lanier, S.M. Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins. *J Biol Chem* **276**, 1585-1593 (2001).
48. Okashah, N. *et al.* Variable G protein determinants of GPCR coupling selectivity. *Proc Natl Acad Sci U S A* **116**, 12054-12059 (2019).
49. Nehme, R. *et al.* Mini-G proteins: Novel tools for studying GPCRs in their active conformation. *PLoS One* **12**, e0175642 (2017).
50. Janicot, R. *et al.* Direct interrogation of context-dependent GPCR activity with a universal biosensor platform. *Cell* **187**, 1527-1546.e1525 (2024).
51. Kleene, S.J. & Kleene, N.K. The native TRPP2-dependent channel of murine renal primary cilia. *Am J Physiol Renal Physiol*, ajprenal.00272.02016 (2016).
52. Gainullin, V.G., Hopp, K., Ward, C.J., Hommerding, C.J. & Harris, P.C. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. *J Clin Invest* **125**, 607-620 (2015).

53. Zheng, W. *et al.* Direct Binding between Pre-S1 and TRP-like Domains in TRPP Channels Mediates Gating and Functional Regulation by PIP2. *Cell reports* **22**, 1560-1573 (2018).
54. Ha, K. *et al.* The heteromeric PC-1/PC-2 polycystin complex is activated by the PC-1 N-terminus. *eLife* **9** (2020).
55. Wang, Z. *et al.* The ion channel function of polycystin-1 in the polycystin-1/polycystin-2 complex. *EMBO reports* **20**, e48336 (2019).
56. Yoshihara, S. *et al.* Cilia at the node of mouse embryos sense fluid flow for left-right determination via Pkd2. *Science* **338**, 226-231 (2012).
57. Walker, R.V. *et al.* Ciliary exclusion of Polycystin-2 promotes kidney cystogenesis in an autosomal dominant polycystic kidney disease model. *Nature communications* **10**, 4072 (2019).
58. Tsiokas, L., Kim, E., Arnould, T., Sukhatme, V.P. & Walz, G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. *Proc Natl Acad Sci U S A* **94**, 6965-6970 (1997).
59. Shen, P.S. *et al.* The Structure of the Polycystic Kidney Disease Channel PKD2 in Lipid Nanodiscs. *Cell* **167**, 763-773.e711 (2016).
60. DeCaen, P.G., Liu, X., Abiria, S. & Clapham, D.E. Atypical calcium regulation of the PKD2-L1 polycystin ion channel. *eLife* **5** (2016).
61. Stoffel, R.H., Randall, R.R., Premont, R.T., Lefkowitz, R.J. & Inglesse, J. Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. *J Biol Chem* **269**, 27791-27794 (1994).
62. Xu, Y. *et al.* The Polycystin-1, Lipoxygenase, and α -Toxin Domain Regulates Polycystin-1 Trafficking. *J Am Soc Nephrol* **27**, 1159-1173 (2016).
63. Yu, W. *et al.* Polycystin-1 protein level determines activity of the Galpha12/JNK apoptosis pathway. *J Biol Chem* **285**, 10243-10251 (2010).

64. Park, E.Y. *et al.* Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. *J Biol Chem* **284**, 7214-7222 (2009).
65. Thivierge, C. *et al.* Overexpression of PKD1 causes polycystic kidney disease. *Mol Cell Biol* **26**, 1538-1548 (2006).
66. Harris, P.C. & Torres, V.E. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. *J Clin Invest* **124**, 2315-2324 (2014).
67. Bergmann, C. *et al.* Polycystic kidney disease. *Nat Rev Dis Primers* **4**, 50 (2018).
68. Baameur, F. *et al.* Role for the regulator of G-protein signaling homology domain of G protein-coupled receptor kinases 5 and 6 in beta 2-adrenergic receptor and rhodopsin phosphorylation. *Mol Pharmacol* **77**, 405-415 (2010).
69. Li, L. *et al.* G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs). *J Biol Chem* **290**, 10775-10790 (2015).
70. Bayly-Jones, C. *et al.* LYCHOS is a human hybrid of a plant-like PIN transporter and a GPCR. *Nature* **634**, 1238-1244 (2024).
71. Xiong, Q. *et al.* Molecular architecture of human LYCHOS involved in lysosomal cholesterol signaling. *Nature structural & molecular biology* **32**, 905-913 (2025).
72. Zhao, J. *et al.* Cryo-EM reveals cholesterol binding in the lysosomal GPCR-like protein LYCHOS. *Nature structural & molecular biology* **32**, 896-904 (2025).
73. Yuasa, T., Takakura, A., Denker, B.M., Venugopal, B. & Zhou, J. Polycystin-1L2 is a novel G-protein-binding protein. *Genomics* **84**, 126-138 (2004).

Acknowledgments

We would like to thank Drs. P. DeAngelis, and X. Zhang for comments on the manuscript; Dr. Feng Qian for human HA-tagged PKD1 and PKD1-T3049V, Dr. Chris Ward for PKD1-eGFP, and Dr. Wenhan Chang for CaSR. This work was supported by grant number R01DK59599 (LT)

and the John S. Gammill Endowed Chair in Polycystic Kidney Disease (LT); F31DK30605 (EPH); R35GM142786 (WLB), R01MH125998 (MA), U54DK126126 (SCP), and R01GM104251 (AAP).

Author Contributions

EPH: performed BRET experiments, analyzed data, and wrote the paper with LT. ANH: performed imaging experiments. MMP: constructed and characterized the PKD2-CRISPR-KO construct. VN: performed immunoblotting experiments on wild-type and PKD1 variants. SEG: prepared PyMOL structures. WLB: assisted with molecular cloning. AAP, MA, HTMH, and SCP: provided reagents. LT: supervised the project and wrote the paper with EPH.

Competing Interests

The authors declare no competing interests.

Figure Legends

Fig. 1. Activation of PKD1 by WNT ligands induces $G\alpha$ - $G\beta\gamma$ dissociation. **a** Schematic representation of the G-CASE BRET assay setup. Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. **b-g** Δ BRET time courses of G-CASE BRET sensors upon WNT-9B, WNT-5A, or WNT-3A addition (1 μ g/ml, time=0 min). **h** Heat map representation of the area under curve (AUC, left panel) and rate constants [k (min^{-1}), right panel] determined from the data shown in (**b-g**). WNT-induced kinetics were analyzed with a plateau followed by one phase dissociation equation. **i** Ligand dose-response curve for $G\alpha_{i3}$ -CASE, plotted as the maximum Δ BRET (%) determined within 6 minutes following WNT-9B stimulation in the kinetic experiments. The curve was fit using a nonlinear three-parameter model. **j** Δ BRET time course of $G\alpha_{i3}$ -CASE in HEK293T cells transiently transfected with pcDNA3 (Control, gray), CRISPR

human PKD1 KO #1-3 (PKD1^{KO}, red), mouse wild-type PKD1 (PKD1^{WT}, blue), or PKD1^{KO}+PKD1^{WT} (purple). Cells were stimulated with WNT-9B (1 μ g/ml, time=0 min). Statistical significance was assessed by one-way ANOVA using Tukey's post-hoc test for multiple comparisons. **k** Quantification of PKD1-dependent luminescence in HEK293T cells transiently transfected with PKD1-Nluc alone (Control), and with different CRISPR human PKD1 KO constructs (PKD1^{KO} #1, PKD1^{KO} #2, PKD1^{KO} #3, combined PKD1^{KO} #1-3). Data are represented as mean \pm SEM of n=3 (**b-i**), n=5 (**j**), or n=4 (**k**) experimental replicates.

Fig. 2. Mutations in PKD1 disrupt WNT-induced G α_i -G β dissociation. **a** Cartoon diagram of PKD1 showing the location (indicated by arrows) mutated in tested constructs (S99I, W139C, T3049V, L4132 Δ , and S4213X). Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. **b-d** Δ BRET time course (left trace) and corresponding AUC (right bar graph) for wild-type (WT) and mutant PKD1 in response to WNT-9B (1 μ g/ml, time=0 min) using G α_{i1} - (**b**), G α_{i2} - (**c**), and G α_{i3} -CASE (**d**) sensors. Data are represented as mean \pm SEM of n=3 experimental replicates (**b-d**). Statistical significance was assessed by one-way ANOVA using Dunnett's post hoc test for multiple comparisons.

Fig. 3. Assessment of the mechanism of G protein coupling selectivity for PKD1. **a** Active state of the CaSR receptor coupled to heterotrimeric G α_{i3} (purple), G β (light blue), and G γ (light green). Assembled using PDB code 8SZH and the extracellular domain of CaSR was removed for simplicity. **b** Depiction of the G α_{i3-s} chimera in which the C-terminal 16 amino acid region of G α_{i3} (purple) within the $\alpha 5$ helix is swapped with that of G α_s (dark blue). **c** Active state of the β_2 AR receptor coupled to heterotrimeric G α_s (dark blue), G β (light blue), and G γ (light green). Assembled using PDB 3SN6. **d** Depiction of the G α_{s-i3} chimera in which the C-terminal 16 amino

acid region of $G\alpha_s$ (dark blue) within the $\alpha 5$ helix is swapped with that of $G\alpha_{i3}$ (purple). **e-g** Δ BRET time courses for $G\alpha_s$ - and $G\alpha_{i3}$ -CASE wild type or chimera sensors with PKD1 (**e**), CaSR (**f**), or β_2 AR (**g**) following agonist stimulation (time=0 min). Data are represented as mean \pm SEM of n=3 experimental replicates (**e-g**).

Fig. 4. WNT-9B induces the recruitment of $G\alpha$ subunits to PKD1 and $G\alpha_i$ -GDP to GTP

exchange. a Schematic representation of the PKD1-Nluc and $G\alpha$ -YFP BRET assay (left panel) and ONE-GO BRET assay (right panel). Created in BioRender. Tsiokas, L. (2026)

<https://BioRender.com/5p1mc32>. **b-e** $G\alpha$ -YFP was titrated with a fixed amount of PKD1-Nluc to assess WNT-independent basal recruitment of $G\alpha_q$ - (**b**), $G\alpha_{i1}$ - (**c**), $G\alpha_{i2}$ - (**d**), and $G\alpha_{i3}$ -YFP (**e**) to PKD1. **f-i** BRET time-courses for PKD1-Nluc and $G\alpha_q$ - (**f**), $G\alpha_{i1}$ - (**g**), $G\alpha_{i2}$ - (**h**), and $G\alpha_{i3}$ -YFP (**i**) in response to WNT-9B (1 μ g/ml, time=0 min). **j-m** Δ BRET time courses for $G\alpha_q$ (**j**), $G\alpha_{i1}$ (**k**), $G\alpha_{i2}$ (**l**), and $G\alpha_{i3}$ (**m**) ONE-GO BRET sensors in the presence or absence of PKD1 upon WNT-9B addition (1 μ g/ml, time=0 min). Data are represented as mean \pm SEM of n=4 (**b-e**) and n=3 (**f-m**) experimental replicates.

Fig. 5. PKD2 enables PKD1 to function as a GPCR. a Δ BRET time course for $G\alpha_{i3}$ -CASE (left trace) and summary data (AUC, right bar graph) for HEK293T cells co-transfected with PKD1 and pcDNA3 (control, gray), CRISPR human PKD2 KO alone (KO, red) or KO in combination with mouse wild-type PKD2 (KO+WT, orange), PKD2-E442G (KO+E442G, blue), PKD2-D509V (KO+D509V, green), PKD2-W199A (KO+W199A, purple), or PKD2-F602P (KO+F602P, yellow). Cells were stimulated with WNT-9B (1 μ g/ml, time=0 min). **b** Δ BRET time course (left panel) and summary data (AUC, right panel) for $G\alpha_{i3}$ -CASE in mIMCD-3 cells. $G\alpha_{i3}$ -CASE and PKD1 were

transiently transfected in wildtype mIMCD-3 cells and assessed either directly in response to WNT-9B (Control, gray) or following pre-treatment with lanthanum (Control+La³⁺). *Pkd2*-null mIMCD-3 cells were transiently transfected the G α_{i3} -CASE, PKD1 and pcDNA3 (KO, red), or with human wild-type PKD2 (KO+WT, orange), PKD2-W201A (KO+W201A, purple), or PKD2-F604P (KO+F604P, yellow). Cells were stimulated with WNT-9B (2 μ g/ml, time=0 min). **c** Subcellular co-localization of C-terminally tagged mouse PKD1 with enhanced GFP (PKD1-eGFP, green) and HaloTag-CAAX construct (HT-CAAX, red) in the presence of untagged wild-type PKD2 (WT), PKD2-D509V (D509V), PKD2-E442G (E442G), PKD2-W201A (W201A), or PKD2-F604P (F604P) in HEK293T cells. Scale bar: 10 μ m. **d** Co-localization of PKD1-eGFP (green) and C-terminally HaloTag-labeled PKD2 (PKD2-HT, red). Arrows indicate cell surface-expression of PKD1-eGFP and PKD2-HaloTag. Scale bar: 10 μ m. **e** Quantification of BRET (left panel) or PKD1-based luminescence (right panel) for PKD1-Nluc and HaloTag-CAAX in HEK293T cells co-transfected with pcDNA3 (Control, gray), CRISPR human PKD2 KO (KO, red) or KO in combination with mouse PKD2-wildtype (KO+WT, orange) or PKD2-E442G (KO+E442G, blue). **f** Net BRET between PKD1-Nluc and wild type PKD2-HaloTag (WT, orange) or PKD2-E442G-HaloTag (E442G, blue). **g** Cartoon illustration to model the chaperone activity of PKD2 in trafficking PKD1 to the cell surface. Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. Data are represented as mean \pm SEM of n=3 (**a-b**, **e-f**) experimental replicates. Statistical significance was assessed by one-way ANOVA using Tukey's post hoc test for multiple comparisons. Live-cell imaging data (**c**, **d**) are shown as representative images from 3 independent experiments.

Fig. 6. PKD1-mediated G α_{i3} activation inhibits cAMP accumulation. a Schematic of the GloSensor cAMP assay. Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. **b** Dose-response curve for forskolin-cAMP accumulation

detected by the pGloSensor-22F cAMP biosensor in HEK293T cells. **c** Analysis of the PKD1-mediated effect on 1 μ M forskolin (FSK)-induced time-dependent cAMP accumulation in HEK293T cells. Time course of cAMP levels before and following WNT stimulation (1 μ g/ml, left panel) and summary data depicting the changes in cAMP concentration (Δ cAMP) 10 min after treatment. **d** Endpoint analysis of PKD1-mediated inhibition of cAMP in HEK293T cells treated with different WNT ligands (1 μ g/ml) followed by 1 μ M FSK in the presence or absence of 0.1 μ g/ml pertussis toxin (PTX). **e** Kinetic analysis of PKD1-mediated basal cAMP changes in response to 1 μ g/ml of WNT-9B (left panel), WNT-5A (center panel), or WNT-3A (right panel) at time=0. **f** Time course (left trace) and summary data (AUC, right bar graph), of basal cAMP changes mediated by wild type and mutant PKD1 in response to WNT-9B (1 μ g/ml, time=0). **g** Endpoint analysis of cAMP levels in HEK293T cells transiently transfected with pGloSensor-22F, PKD1, and either pcDNA3 (Control, gray), CRISPR human PKD2 KO (KO, red), or PKD2 KO+mouse wild type PKD2 (KO+WT, orange). **h** Endpoint analysis of cAMP levels in wild type (Control, gray) or stable PKD2 KO (KO, red) mIMCD-3 cells transiently transfected with pGloSensor-22F and PKD1. Cells were stimulated with 2 μ g/ml WNT-9B. **i** Diagrammatic representation of a model for the regulation of cytosolic cAMP levels by PKD1/PKD2. In the model, regulation of cAMP levels is regulated via a direct effect of WNT-activated PKD1/PKD2 on $G\alpha_{i1-3}$ subunits. Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. Data are represented as mean \pm SEM of n=3 (**b-h**) experimental replicates. Statistical significance was assessed by one-way ANOVA using Tukey's post hoc test for multiple comparisons.

Fig. 7. GRK6 associates and promotes internalization of PKD1. **a-d** GRK3- (**a**), GRK5- (**b**), GRK2- (**c**), and GRK6-HaloTag (**d**) were titrated with a fixed amount of PKD1-Nluc to assess

basal recruitment to PKD1. Recruitment of GRK2- and GRK6-HaloTag was assessed in HEK293T cells co-transfected with pcDNA3 (- PKD2, cyan for GRK2-HaloTag, blue for GRK6-HaloTag), wild-type PKD2 (WT, orange), or PKD2- Δ C (Δ C, pink). **e** Co-localization of C-terminally tagged mouse PKD1 with enhanced GFP (PKD1-eGFP, green) and GRK6-HaloTag (red) in the presence of untagged wild type PKD2 (WT, upper panels) or PKD2- Δ C (Δ C, lower panels) in HEK293T cells. **f** Co-localization of PKD1-eGFP (green) and the HaloTag-CAAX construct (red) in the presence of untagged wild-type PKD2 (WT, upper panels) or PKD2- Δ C (Δ C, lower panels) in HEK293T cells. Arrows indicate cell surface-expression, scale bar: 10 μ m (**e, f**). **g** Quantification of BRET (left panel) and PKD1-based luminescence (right panel) for PKD1-Nluc and HaloTag-CAAX in HEK293T cells co-transfected with untagged GRK6 at varied concentrations. Statistical significance was assessed by one-way ANOVA using Dunnett's post hoc test for multiple comparisons. **h** Δ BRET time courses for $G_{\alpha_{i3}}$ -CASE in HEK293T cells transiently co-transfected with PKD1 and pcDNA3 (- GRK6, gray square) or with untagged GRK6 (+ GRK6, blue circle). Cells were pretreated with DMSO (left panel), GRK6-IN-1 (25 μ M, center panel), and GRK6-IN-2 (25 μ M, right panel) for 1 hour before WNT-stimulation (1 μ g/ml, time=0 min). Data are represented as mean \pm SEM of n=3 (**a-d, g, h**) experimental replicates. Live-cell imaging data (**e-f**) are shown as representative images from 3 independent experiments.

Fig. 8. ARRB2 functions downstream of GRK6 in mediating internalization of the PKD1/PKD2 complex. **a, b** ARRB1- (**a**) and ARRB2-HaloTag (**b**) ARRB-HaloTag were titrated with a fixed amount of PKD1-Nluc to assess basal recruitment to PKD1. **c** Δ BRET time course (left panel) and summary data (AUC, right panel) for ARRB2-HaloTag recruitment to PKD1 and/or PKD2. HEK293T cells were transiently transfected with ARRB2-HaloTag, PKD1-Nluc,

and pcDNA3 (PKD1-Nluc, gray circle) or PKD2 (PKD1-Nluc + PKD2, pink circle). Vice versa, cells were transfected with ARRB2-HaloTag, PKD2-Nluc, and pcDNA3 (PKD2-Nluc, gray square) or PKD1 (PKD2-Nluc + PKD1, pink square), and responses recorded before and after WNT-9B addition (1 μ g/ml, time=0 min). Statistical significance was assessed by one-way ANOVA using Tukey's post hoc test for multiple comparisons. **d** Δ BRET time course (left trace) and summary data (AUC, right bar graph) for ARRB2-HaloTag recruitment to PKD1-Nluc in response to WNT-9B (1 μ g/ml, time=0 min) following pre-incubation with DMSO or GRK6-IN-1 + GRK6-IN-2 (15 μ M) for 1 hour. Statistical significance was assessed by unpaired t test with Welch's correction (two-tailed). **e** Quantification of basal BRET for HaloTag (HT)-CAAX, HT-Rab5, or HT-FYVE and PKD1-Nluc (left panel) or PKD2-Nluc (right panel). **f** Kinetic analysis of Δ BRET for HT-CAAX, HT-Rab5, or HT-FYVE and PKD1-Nluc (left trace) or PKD2-Nluc (right trace) in response to WNT-9B (1 μ g/ml, time=0 min). **g** Δ BRET time course for PKD1-Nluc and HT-CAAX in response to WNT-9B following pre-incubation with barbadin (100 μ M). **h** Diagrammatic presentation of a model for the function of GRK6 and ARRB2 in PKD1-mediated signaling. In the model, GRK6 and ARRB2 function within a pathway that signals PKD1 internalization and/or ARRB-mediated signaling following WNT activation of PKD1. Created in BioRender. Tsiokas, L. (2026) <https://BioRender.com/5p1mc32>. Data are represented as mean \pm SEM of n=3 (**a, b, e-g**) or n=4 (**c, d**) experimental replicates.

Editorial summary:

The human genome contains approximately 800 G protein-coupled receptors (GPCRs), all characterized by a common 7-transmembrane domain architecture. Here, the authors show that PKD1, an 11-transmembrane protein with a noncanonical transient receptor potential (TRP) channel architecture, functions as a GPCR with unique biochemical properties.

Peer review information: *Nature Communications* thanks Robin Maser, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

ARTICLE IN PRESS















